We have a highly experienced Board and Senior Executive Team. The Board sets the Company’s strategy and policies, and monitors progress towards meeting our objectives. This includes regular reviews of financial performance and critical business issues. The Senior Executive Team, led by Chief Executive Officer David Brennan, focuses on the day-to-day running of our business operations and our Company development, regularly reviewing and deciding all major business issues.
Senior Executive Team
David Brennan
- Chief Executive Officer
Simon Lowth
- Chief Financial Officer
Anders Ekblom
- Executive Vice-President, Development
David Smith
- Executive Vice-President, Operations
Jan Lundberg
- Executive Vice-President, Discovery Research
Jeff Pott
- General Counsel
The Board
Louis Schweitzer
- Non-Executive Chairman
Chairman of the Nomination and Governance Committee, member of the Remuneration Committee
-
David Brennan
- Executive Director
Chief Executive Officer
-
Simon Lowth
- Executive Director
Chief Financial Officer
Jane Henney
- Non-Executive Director
Member of the Audit Committee, the Nomination and Governance Committee and the Science Committee
Marcus Wallenberg
- Non-Executive Director
Dame Nancy Rothwell
- Non-Executive Director
Chairman of the Science Committee, member of the Remuneration Committee
Bo Angelin
- Non-Executive Director
Member of the Science Committee
Michele Hooper
- Senior Non-Executive Director
Member of the Audit Committee, member of the Nomination and Governance Committee
John Varley
- Non-Executive Director
Chairman of the Remuneration Committee, member of the Nomination and Governance Committee
John Buchanan
- Non-Executive Director
Chairman of the Audit Committee, member of the Remuneration Committee
Jean-Philippe Courtois
- Non-Executive Director
Member of the Audit Committee
Rudy Markham
- Non-Executive Director
Member of the Audit Committee
| Board Committee remits |
|---|
The remits for AstraZeneca's Board Committees are available to view/download here: |
Not signed in
Page tools
Share price
- London
-
26.50 GBP - New York
-
43.37 USD - Stockholm
-
336.00 SEK
At 04-Jul-2009 15:24 GMT
Detailed share priceOur responsibility
We continue to communicate openly on a range of issues, including:
